Immunotherapy – Oncology Pharmacist Brief
Immunotherapy uses drugs to enhance or restore the immune system’s ability to recognize and destroy cancer cells. It includes several classes such as:
- Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) that block inhibitory pathways like PD-1/PD-L1 or CTLA-4, allowing T-cells to attack tumors.
- Monoclonal antibodies targeting tumor-specific antigens.
- CAR-T cell therapy, where patient’s T-cells are engineered to target cancer.
Key Points for Pharmacists:
- Indicated in various cancers including melanoma, lung, bladder, and certain breast cancers (e.g., triple-negative).
- Adverse effects are often immune-related (irAEs) such as colitis, pneumonitis, hepatitis, endocrinopathies.
- Requires close monitoring and prompt management of irAEs, often with corticosteroids or immunosuppressants.
- Patient education on symptom recognition (e.g., diarrhea, cough, fatigue) is essential.
- Coordination with the oncology team for timely intervention improves safety and outcomes.
Here’s a concise immunotherapy summary table tailored for oncology pharmacists:
| Immunotherapy Class | Examples | Mechanism of Action | Key Indications | Common Immune-Related Adverse Events (irAEs) | Monitoring & Pharmacist Role |
|---|---|---|---|---|---|
| Immune Checkpoint Inhibitors | Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab | Block PD-1, PD-L1, or CTLA-4 to enhance T-cell activation | Melanoma, NSCLC, bladder cancer, TNBC, Hodgkin lymphoma | Colitis, pneumonitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency) | Monitor for symptoms of irAEs; educate patients on early signs; manage irAEs with steroids per guidelines |
| Monoclonal Antibodies | Rituximab, Trastuzumab | Target tumor-specific antigens to induce immune destruction or inhibit growth | NHL, HER2+ breast cancer | Infusion reactions, rash, cardiac toxicity (trastuzumab) | Pre-medicate to reduce infusion reactions; monitor cardiac function for HER2 agents |
| CAR-T Cell Therapy | Tisagenlecleucel, Axicabtagene ciloleucel | Patient T-cells engineered to target cancer cells | Certain leukemias and lymphomas | Cytokine release syndrome, neurotoxicity | Monitor for CRS and neurotoxicity; coordinate ICU support; educate on urgent symptom reporting |
| Cytokine Therapies | Interleukin-2, Interferons | Stimulate immune cell proliferation and activation | Melanoma, renal cell carcinoma | Flu-like symptoms, capillary leak syndrome | Monitor vital signs, fluids, educate on side effects and supportive care |
Pharmacist Tips:
- Immunotherapy toxicities can occur weeks to months after starting treatment — vigilance is essential.
- Early recognition and prompt corticosteroid treatment for irAEs can prevent serious complications.
- Patient counseling should emphasize immediate reporting of symptoms like diarrhea, cough, or fatigue.
- Coordinate multidisciplinary care including oncology, endocrinology, and ICU teams as needed.